Quick Answer
CytomX Therapeutics, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $76.20 million for the year ending 2025.
- CytomX Therapeutics, Inc. showed a decrease of -44.8% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from CytomX Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), CytomX Therapeutics, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 493.2%.
- Historical annual values: Fiscal year 2025: $76.20 million | Fiscal year 2024: $138.10 million | Fiscal year 2023: $101.21 million | Fiscal year 2022: $53.16 million | Fiscal year 2021: $37.31 million | Fiscal year 2020: $100.36 million | Fiscal year 2019: $57.49 million | Fiscal year 2018: $59.50 million | Fiscal year 2017: $71.62 million | Fiscal year 2016: $12.85 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: